Evidence map›Paper›PMID 39560416›Full record

ReviewPain2024

"Neuroinflammation": does it have a role in chronic pain? Evidence from human imaging.

Marco L Loggia

Abstract readReview
In one paragraph

Review in Pain, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Glial cells in neuropathic pain.Physiological reviews · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Marco L LoggiaDepartment of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, United States.ORCID 0000-0002-8026-5265

Funding

Imaging neuroglial mechanisms of neuropathic pain-opioid interaction in HIVR01DA047088 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LOGGIA, MARCO LUCIANO, RATAI, EVA-MARIA · 2018 to 2022
$4.3M
Evaluation of Cannabidiol for Reduction of Brain NeuroinflammationR01DA053316 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI GILMAN, JODI, LOGGIA, MARCO LUCIANO · 2021 to 2025
$3.9M
In-vivo imaging of spinal and brain glial activation in low back pain patientsR01NS095937 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI LOGGIA, MARCO LUCIANO · 2016 to 2020
$3.5M
The Role of Brain Glial Activation in knee OstoarthritisR01NS094306 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI LOGGIA, MARCO LUCIANO · 2016 to 2020
$3.5M
The role of neuroinflammation in human peripheral neuropathic painR01AR079110 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI Marco Luciano Loggia, VITALY NAPADOW · 2022 to 2026
$2.9M
The Role of Neuroimmune Activation in Chronic Pain and Negative AffectR21NS087472 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI LOGGIA, MARCO LUCIANO · 2014 to 2015
$479k
PET/MRI Imaging of Neuraxial Inflammation in Sciatica PatientsR21NS082548 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI HOOKER, JACOB M., ZHANG, YI · 2013 to 2014
$476k
NIAMS NIH HHS R01 AR079110NIAMS NIH HHS R01-AR079110-01A1NIDA NIH HHS R01 DA047088NIDA NIH HHS R01-DA047088-01NIDA NIH HHS R01 DA053316NIDA NIH HHS R01-DA053316-01NINDS NIH HHS R01 NS094306NINDS NIH HHS R01 NS095937NINDS NIH HHS R01- NS095937-01A1NINDS NIH HHS R21 NS082548NINDS NIH HHS R21-NS082548-01A1NINDS NIH HHS R21 NS087472NINDS NIH HHS R21-NS087472-01A1U.S. Department of Defense W81XWH-14-1-0543
6 · The paper itself

Abstract

abstractDespite hundreds of studies demonstrating the involvement of neuron-glia-immune interactions in the establishment and/or maintenance of persistent pain behaviors in animals, the role (or even occurrence) of so-called "neuroinflammation" in human pain has been an object of contention for decades. Here, I present the results of multiple positron emission tomography (PET) studies measuring the levels of the 18 kDa translocator protein (TSPO), a putative neuroimmune marker, in individuals with various pain conditions. Overall, these studies suggest that brain TSPO PET signal: (1) is elevated, compared to healthy volunteers, in individuals with chronic low back pain (with additional elevations in spinal cord and neuroforamina), fibromyalgia, migraine and other conditions characterized by persistent pain; (2) has a spatial distribution exhibiting a degree of disorder specificity; (3) is parametrically linked to pain characteristics or comorbid symptoms (eg, nociplastic pain, fatigue, depression), as well as measures of brain function (ie, functional connectivity), in a regionally-specific manner. In this narrative, I also discuss important caveats to consider in the interpretation of this work (eg, regarding the cellular source of the signal and the complexities inherent in its acquisition and analysis). While the biological and clinical significance of these findings awaits further work, this emerging preclinical literature supports a role of neuron-glia-immune interactions as possible pathophysiological underpinnings of human chronic pain. Gaining a deeper understanding of the role of neuroimmune function in human pain would likely have important practical implications, possibly paving the way for novel interventions.

Indexed as

Chronic PainNeuroinflammatory DiseasesPositron-Emission TomographyBrainHumansReceptors, GABAReceptors, GABATSPO protein, human

Identifiers

PMID39560416
PMCPMC11729497

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.